Awaiting development: Guidance and quality standards

Showing 111 to 120 of 323

Guidance and quality standards awaiting development
Title	Type
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Extra-vascular implantable cardioverter defibrillator (EVICD) for people with a defibrillator	Interventional procedures guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]	Technology appraisal guidance
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]	Technology appraisal guidance
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]	Technology appraisal guidance
Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [TSID12216]	Technology appraisal guidance
Filgotinib for Axial spondyloarthritis [ID6594]	Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance
Galcanezumab for migraine [TSID10663]	Technology appraisal guidance
Gambling	Quality standard